Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA1 | P00915 | 3/20 | 0.42 |
| ▸ | CA2 | P00918 | 3/20 | 0.42 |
| ▸ | CA9 | Q16790 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.42 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 3/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | AGER | Q15109 | 1/20 | 0.36 |
| ▸ | MYC | P01106 | 1/20 | 0.36 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.36 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.35 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21155118 | 0.84 | ATR (0.43) | ATRCA12CA1CA2CA9 | |
| SCHEMBL24162849 | 0.81 | ATR (0.43) | ATRCA12CA1CA2CA9 | |
| SCHEMBL1082793 | 0.79 | CA12 (0.54) | ATRCA12CA1CA2CA9 | |
| SCHEMBL11226680 | 0.78 | MAPT (0.40) | ATRCA12CA1CA2CA9 | |
| SCHEMBL30339006 | 0.78 | ACHE (0.53) | ATRCA12CA1CA2CA9 | |
| SCHEMBL14862238 | 0.78 | ACHE (0.53) | ATRCA12CA1CA2CA9 | |
| SCHEMBL2934675 | 0.78 | CA12 (0.54) | ATRCA12CA1CA2CA9 | |
| SCHEMBL3677780 | 0.78 | XDH (0.54) | ATRCA12CA1CA2CA9 | |
| SCHEMBL9081119 | 0.78 | SMN1; SMN2 (0.66) | ATRCA12CA1CA2CA9 | |
| SCHEMBL27828990 | 0.78 | GAA (0.46) | CA12CA1CA9SMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9394241-B2 | Composition and method for making oligo-benzamide compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2016-07-19 | — | — | US | disclosed |
| US-20140127285-A1 | Composition and Method for Making Oligo-Benzamide Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2014-05-08 | — | — | US | disclosed |
| US-8618324-B2 | Composition and method for making oligo-benzamide compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2013-12-31 | — | — | US | disclosed |
| US-20100317570-A1 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-12-16 | — | — | US | disclosed |
| US-7816324-B2 | Composition and method for the treatment of diseases affected by a peptide receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-10-19 | — | — | US | disclosed |
| US-20090012141-A1 | Composition and Method for Making Oligo-Benzamide Compounds | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2009-01-08 | — | — | US | disclosed |
| US-20080300193-A1 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008112939-A2 | COMPOSITION AND METHOD FOR MAKING OLIGO-BENZAMIDE COMPOUNDS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112938-A2 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY A PEPTIDE RECEPTOR | NEW ENGLAND MEDICAL CENTER HOSPITALS, INC. (US) | 2008-09-18 | — | — | WO | disclosed |
| WO-2008112941-A1 | COMPOSITION AND METHOD FOR THE TREATMENT OF DISEASES AFFECTED BY A PEPTIDE RECEPTOR | BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127285-A1 | Composition and Method for Making Oligo-Benzamide Compounds | OTC, ODC1, MOGAT2 | ATR 1949/4885CA12 2411/4885CA1 3759/4885 |
| US-20100317570-A1 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor | GPR119, INSR, GLP1R | ATR 4510/4885CA12 2775/4885CA1 4313/4885 |
| US-20090012141-A1 | Composition and Method for Making Oligo-Benzamide Compounds | OTC, ODC1, MOGAT2 | ATR 1949/4885CA12 2411/4885CA1 3759/4885 |
| US-20080300193-A1 | Composition and Method for the Treatment of Diseases Affected by a Peptide Receptor | GPR119, INSR, GLP1R | ATR 4510/4885CA12 2775/4885CA1 4313/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.